{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:57:43Z","timestamp":1793152663523,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175052","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:31:54Z","timestamp":1653521514000},"page":"175052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Treatment with the soluble guanylate cyclase activator BAY 60\u20132770 normalizes bladder function in an in vivo rat model of chronic prostatitis"],"prefix":"10.1016","volume":"927","author":[{"given":"Ozgu","family":"Aydogdu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Aronsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Uyar Gocun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-4713","authenticated-orcid":false,"given":"Michael","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175052_bib1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2022.175052_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.autneu.2010.08.008","article-title":"Pharmacological modulation of the micturition pattern in normal and cyclophosphamide pre-treated conscious rats","volume":"159","author":"Andersson","year":"2011","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.ejphar.2022.175052_bib3","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/bjp.2008.6","article-title":"Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide-induced cystitis of the anaesthetized rat","volume":"153","author":"Andersson","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175052_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1464-410X.2006.06003.x","article-title":"Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes","volume":"97","author":"Angelico","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175052_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12894-021-00882-9","article-title":"Cross-organ sensitization between the prostate and bladder in an experimental rat model of lipopolysaccharide (LPS)-induced chronic pelvic pain syndrome","volume":"21","author":"Aydogdu","year":"2021","journal-title":"BMC Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/pros.24101","article-title":"Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats","volume":"81","author":"Aydogdu","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2022.175052_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1464-410X.2007.06667.x","article-title":"A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis\/chronic pelvic pain syndrome","volume":"99","author":"Bates","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175052_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11302-013-9395-y","article-title":"Purinergic signalling in the urinary tract in health and disease","volume":"10","author":"Burnstock","year":"2014","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejphar.2022.175052_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2016.04.023","article-title":"Soluble guanylate cyclase modulators, BAY 41-2272 and BAY 60-2770, inhibit human and rabbit prostate contractility","volume":"94","author":"Calmasini","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2022.175052_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175052_bib11","doi-asserted-by":"crossref","first-page":"F85","DOI":"10.1152\/ajprenal.00041.2016","article-title":"Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice","volume":"311","author":"de Oliveira","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2022.175052_bib12","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.juro.2012.01.072","article-title":"Nitric oxide signaling pathways involved in the inhibition of spontaneous activity in the Guinea pig prostate","volume":"187","author":"Dey","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuroscience.2013.02.041","article-title":"Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats","volume":"240","author":"Fan","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2022.175052_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bju.14988","article-title":"Pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome: a Cochrane systematic review","volume":"125","author":"Franco","year":"2020","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175052_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/nau.22665","article-title":"Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor","volume":"34","author":"Fullhase","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2022.175052_bib16","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1113\/JP277452","article-title":"Bladder overactivity and afferent hyperexcitability induced by prostate-to-bladder cross-sensitization in rats with prostatic inflammation","volume":"597","author":"Funahashi","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2022.175052_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.eururo.2011.06.037","article-title":"Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"60","author":"Gacci","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.14122","article-title":"Tadalafil is sufficiently effective for severe chronic prostatitis\/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia","volume":"27","author":"Hiramatsu","year":"2020","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib19","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/01.ju.0000144761.69398.be","article-title":"Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis","volume":"172","author":"Hosseini","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib20","doi-asserted-by":"crossref","first-page":"R574","DOI":"10.1152\/ajpregu.00465.2002","article-title":"COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat","volume":"284","author":"Hu","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2022.175052_bib21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/andr.12273","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model","volume":"4","author":"Hu","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.ejphar.2022.175052_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopha.2018.06.139","article-title":"Role of oxidative stress in pathology of chronic prostatitis\/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress","volume":"106","author":"Ihsan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175052_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/pros.23518","article-title":"Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia","volume":"78","author":"Inamura","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2022.175052_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00345-008-0303-y","article-title":"The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms","volume":"26","author":"Kedia","year":"2008","journal-title":"World J. Urol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2022.175052_bib25","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ijantimicag.2007.08.028","article-title":"Epidemiology of prostatitis","volume":"31","author":"Krieger","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2022.175052_bib26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.juro.2007.05.116","article-title":"Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation","volume":"178","author":"Kumar","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib27","doi-asserted-by":"crossref","first-page":"H1670","DOI":"10.1152\/ajpheart.00062.2013","article-title":"The sGC activator BAY 60-2770 has potent erectile activity in the rat","volume":"304","author":"Lasker","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2022.175052_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2013.09.020","article-title":"The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice","volume":"191","author":"Leiria","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib29","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/01.ju.0000110501.96416.40","article-title":"Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis","volume":"171","author":"Logadottir","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.eururo.2015.08.061","article-title":"Contemporary management of chronic prostatitis\/chronic pelvic pain syndrome","volume":"69","author":"Magistro","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrurol.2017.181","article-title":"Stimulators and activators of soluble guanylate cyclase for urogenital disorders","volume":"15","author":"Monica","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib32","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/bjp.2008.39","article-title":"Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity","volume":"153","author":"Monica","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175052_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/pros.23514","article-title":"Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis","volume":"78","author":"Okamoto","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2022.175052_bib35","doi-asserted-by":"crossref","first-page":"H792","DOI":"10.1152\/ajpheart.00953.2010","article-title":"Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme","volume":"300","author":"Pankey","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2022.175052_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.564","article-title":"Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis","volume":"8","author":"Patel","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ejphar.2022.175052_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","author":"Schmidt","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175052_bib38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.juro.2016.03.077","article-title":"Chronic prostatitis induces bladder hypersensitivity and sensitizes bladder afferents in the mouse","volume":"196","author":"Schwartz","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.juro.2012.08.088","article-title":"The prevalence and overlap of interstitial cystitis\/bladder pain syndrome and chronic prostatitis\/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study","volume":"189","author":"Suskind","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175052_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pros.20061","article-title":"Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium","volume":"61","author":"Wang","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2022.175052_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/297295","article-title":"Signalling molecules in the urothelium","volume":"2014","author":"Winder","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2022.175052_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/pros.23447","article-title":"Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue","volume":"78","author":"Yellepeddi","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2022.175052_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/1557988320903200","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: a disease or symptom? Current perspectives on diagnosis, treatment, and prognosis","volume":"14","author":"Zhang","year":"2020","journal-title":"Am. J. Men's Health"},{"key":"10.1016\/j.ejphar.2022.175052_bib44","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1590\/S0100-879X2009005000021","article-title":"Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA)","volume":"42","author":"Zhao","year":"2009","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:02:57Z","timestamp":1757977377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":44,"alternative-id":["S0014299922003132"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175052","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with the soluble guanylate cyclase activator BAY 60\u20132770 normalizes bladder function in an in vivo rat model of chronic prostatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175052"}}